Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from CSPC Pharmaceutical Group ( (HK:1093) ).
CSPC Pharmaceutical Group has announced the approval of its new drug, JMT206, for clinical trials in China. This recombinant fully human anti-ActRIIA/IIB monoclonal antibody is designed to aid in weight management for individuals with obesity or overweight conditions, showing promising efficacy and safety in preclinical studies. The approval marks a significant step in the company’s efforts to enhance its market position in the weight management sector.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$11.05 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a Hong Kong-based company operating in the pharmaceutical industry. It focuses on developing innovative drugs, with a particular emphasis on treatments that address muscle mass maintenance and weight management.
Average Trading Volume: 145,949,219
Technical Sentiment Signal: Buy
Current Market Cap: HK$86.96B
For an in-depth examination of 1093 stock, go to TipRanks’ Overview page.